- Home
- VRAR vs COEP Comparison
VRAR vs COEP Comparison
Compare VRAR & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- COEP
- Stock Information
- Founded
- VRAR 2016
- COEP 2017
- Country
- VRAR United States
- COEP United States
- Employees
- VRAR N/A
- COEP N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRAR Technology
- COEP Health Care
- Exchange
- VRAR Nasdaq
- COEP Nasdaq
- Market Cap
- VRAR 31.5M
- COEP 27.4M
- IPO Year
- VRAR 2021
- COEP N/A
- Fundamental
- Price
- VRAR $1.44
- COEP $10.92
- Analyst Decision
- VRAR Strong Buy
- COEP
- Analyst Count
- VRAR 1
- COEP 0
- Target Price
- VRAR $2.62
- COEP N/A
- AVG Volume (30 Days)
- VRAR 975.0K
- COEP 55.9K
- Earning Date
- VRAR 09-29-2025
- COEP 08-15-2025
- Dividend Yield
- VRAR N/A
- COEP N/A
- EPS Growth
- VRAR N/A
- COEP N/A
- EPS
- VRAR N/A
- COEP N/A
- Revenue
- VRAR $8,756,789.00
- COEP $62,874.00
- Revenue This Year
- VRAR $23.96
- COEP N/A
- Revenue Next Year
- VRAR $12.15
- COEP N/A
- P/E Ratio
- VRAR N/A
- COEP N/A
- Revenue Growth
- VRAR N/A
- COEP N/A
- 52 Week Low
- VRAR $0.50
- COEP $2.31
- 52 Week High
- VRAR $7.00
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- VRAR 46.20
- COEP 57.24
- Support Level
- VRAR $1.52
- COEP $11.30
- Resistance Level
- VRAR $1.77
- COEP $12.71
- Average True Range (ATR)
- VRAR 0.17
- COEP 0.91
- MACD
- VRAR -0.00
- COEP 0.09
- Stochastic Oscillator
- VRAR 22.73
- COEP 47.27
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.